Blinatumomab is a bispecific T-cell–engaging antibody that binds CD3+ T cells and CD19+ leukemia cells, inducing cytotoxic immune responses that lyse CD19-expressing B cells via activated T cells (3). Here, CD19 is linked to leukemia.